Dronedarone

Dronedarone, sold as Multaq, is a medicine taken by mouth that the US label describes as an antiarrhythmic drug. The label read lists one use: lowering the chance of being admitted to hospital for atrial fibrillation, for patients in sinus rhythm with a history of paroxysmal or persistent atrial fibrillation. The label says the mechanism of action is unknown and that the medicine has antiarrhythmic properties belonging to all four Vaughan-Williams classes. It carries a boxed warning: in patients with symptomatic heart failure and recent decompensation requiring hospitalization, or NYHA class IV heart failure, the medicine doubles the risk of death, and for those with permanent atrial fibrillation it doubles the risk of death, of stroke and of hospital admission for heart failure.

Also called Multaq

  • Drug
  • In this atlas

Overview

Technical summary

RxNorm ingredient 233698 (dronedarone); UNII JQZ1L091Y2 (exact: the openFDA record of the label lists it and RxNorm gives it for the ingredient); the label describes the hydrochloride salt (RxNorm 736680). MeSH descriptor D000077764 is Dronedarone; its record lists the pharmacological action Anti-Arrhythmia Agents and says dronedarone was indexed under amiodarone analogs and derivatives from 1999 to 2018. RxClass lists the FDA established pharmacologic class Antiarrhythmic, and the openFDA record of the label carries the same class (Antiarrhythmic [EPC]). The label read is the Sanofi-Aventis U.S. LLC label for Multaq tablets, application NDA022425, effective 2025-05-29 in openFDA. This page records label indications, the class, the mechanism sentences and the boxed warning only: no trial result and no dose is given.

About this drug

Level
Substance
Mechanism
The label says the mechanism of action of dronedarone is unknown; it has antiarrhythmic properties belonging to all four Vaughan-Williams classes, but the contribution of each to the clinical effect is unknown.

Claims and evidence

Context Patients in sinus rhythm with a history of paroxysmal or persistent atrial fibrillation, as described in the US label of Multaq

Recipient
Recipient not specified
Population
Patients described in the indications section of the label: patients in sinus rhythm with a history of paroxysmal or persistent atrial fibrillation. The passages read do not state an age range.
Care setting
Prescription medicine, as described in the US label
Geography
United States (label of the US Food and Drug Administration)
Life stage
Not stated in the label passages read
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
Included
  • Patients in sinus rhythm with a history of paroxysmal or persistent atrial fibrillation
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    The US label of Multaq (dronedarone tablets, Sanofi-Aventis U.S. LLC, application NDA022425; the version dated 2025-05-29 in openFDA) describes dronedarone as an antiarrhythmic drug. It lists reducing the risk of hospitalization for atrial fibrillation in patients in sinus rhythm with a history of paroxysmal or persistent atrial fibrillation.

    Applies to Recipient not specified Patients in sinus rhythm with a history of paroxysmal or persistent atrial fibrillation, as described in the US label of Multaq

    Certainty method
    Not assessed
    Limitations
    This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Contraindications, other warnings, interactions and dosing were not recorded. A second openFDA Multaq record from a repackager was not read. openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-18
    Next evidence check due
    Not scheduled
    Sources and citations (3)
    1. Supports openFDA drug label record for Multaq (dronedarone tablets), Sanofi-Aventis U.S. LLC label: indications, mechanism, class, boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 7fa41601-7fb5-4155-8e50-2ae903f0d2d6 (manufacturer Sanofi-Aventis U.S. LLC, application NDA022425), returned on 2026-11-18. The label text is dated 2025-05-29 (effective_time). A second openFDA Multaq record (Cardinal Health 107, LLC, a repackager) exists and was not used.

      Locator
      results[0].indications_and_usage[0], highlights sentence
      How it applies
      Label passage quoted in the research quote table (LB-04).
      Retrieved
      Source effective date
      2025-05-29
      Source state
      Current
      Version fingerprint
      54147fc8a2984100b211341d515c2f61f7f9f0d9415ddba75659fe6d841df662
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Supports openFDA drug label record for Multaq (dronedarone tablets), Sanofi-Aventis U.S. LLC label: indications, mechanism, class, boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 7fa41601-7fb5-4155-8e50-2ae903f0d2d6 (manufacturer Sanofi-Aventis U.S. LLC, application NDA022425), returned on 2026-11-18. The label text is dated 2025-05-29 (effective_time). A second openFDA Multaq record (Cardinal Health 107, LLC, a repackager) exists and was not used.

      Locator
      results[0].indications_and_usage[0], indication statement
      How it applies
      Label passage quoted in the research quote table (LB-05, LB-06).
      Retrieved
      Source effective date
      2025-05-29
      Source state
      Current
      Version fingerprint
      54147fc8a2984100b211341d515c2f61f7f9f0d9415ddba75659fe6d841df662
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    3. Background openFDA drug label record for Multaq (dronedarone tablets), Sanofi-Aventis U.S. LLC label: indications, mechanism, class, boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 7fa41601-7fb5-4155-8e50-2ae903f0d2d6 (manufacturer Sanofi-Aventis U.S. LLC, application NDA022425), returned on 2026-11-18. The label text is dated 2025-05-29 (effective_time). A second openFDA Multaq record (Cardinal Health 107, LLC, a repackager) exists and was not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20250529.
      Retrieved
      Source effective date
      2025-05-29
      Source state
      Current
      Version fingerprint
      54147fc8a2984100b211341d515c2f61f7f9f0d9415ddba75659fe6d841df662
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

Context Patients with decompensated heart failure or permanent atrial fibrillation, as described in a US Multaq label boxed warning

Recipient
Recipient not specified
Population
Patients with symptomatic heart failure and recent decompensation requiring hospitalization, patients with NYHA class IV heart failure, and patients with permanent atrial fibrillation, as the boxed warning describes the risks. The passages read give no age range.
Care setting
Prescription medicine, as described in the US label
Geography
United States (label of the US Food and Drug Administration)
Life stage
Not stated in the label passages read
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (label statement)
Eligibility: 2 inclusion criteria; exclusion criteria not stated
Included
  • Patients with symptomatic heart failure and recent decompensation requiring hospitalization, or NYHA class IV heart failure
  • Patients with permanent atrial fibrillation
Excluded
None stated
  • Safety Evidence stage not applicable Certainty not assessed

    The same US label carries a boxed warning on an increased risk of death, stroke and heart failure in patients with decompensated heart failure or permanent atrial fibrillation. It says that in patients with symptomatic heart failure and recent decompensation requiring hospitalization, or NYHA class IV heart failure, the medicine doubles the risk of death, and that for those with permanent atrial fibrillation it doubles the risk of death, of stroke and of hospital admission for heart failure.

    Applies to Recipient not specified Patients with decompensated heart failure or permanent atrial fibrillation, as described in a US Multaq label boxed warning

    Certainty method
    Not assessed
    Limitations
    This claim records the label's boxed warning statements of risk only. The warning also states two contraindications; those are the label's and are not repeated as advice. Other warnings, contraindications and interactions were not recorded. openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-18
    Next evidence check due
    Not scheduled
    Sources and citations (3)
    1. Supports openFDA drug label record for Multaq (dronedarone tablets), Sanofi-Aventis U.S. LLC label: indications, mechanism, class, boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 7fa41601-7fb5-4155-8e50-2ae903f0d2d6 (manufacturer Sanofi-Aventis U.S. LLC, application NDA022425), returned on 2026-11-18. The label text is dated 2025-05-29 (effective_time). A second openFDA Multaq record (Cardinal Health 107, LLC, a repackager) exists and was not used.

      Locator
      results[0].boxed_warning[0], first paragraph, heart failure
      How it applies
      Label passage quoted in the research quote table (LB-09).
      Retrieved
      Source effective date
      2025-05-29
      Source state
      Current
      Version fingerprint
      54147fc8a2984100b211341d515c2f61f7f9f0d9415ddba75659fe6d841df662
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Supports openFDA drug label record for Multaq (dronedarone tablets), Sanofi-Aventis U.S. LLC label: indications, mechanism, class, boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 7fa41601-7fb5-4155-8e50-2ae903f0d2d6 (manufacturer Sanofi-Aventis U.S. LLC, application NDA022425), returned on 2026-11-18. The label text is dated 2025-05-29 (effective_time). A second openFDA Multaq record (Cardinal Health 107, LLC, a repackager) exists and was not used.

      Locator
      results[0].boxed_warning[0], first paragraph, permanent atrial fibrillation
      How it applies
      Label passage quoted in the research quote table (LB-10).
      Retrieved
      Source effective date
      2025-05-29
      Source state
      Current
      Version fingerprint
      54147fc8a2984100b211341d515c2f61f7f9f0d9415ddba75659fe6d841df662
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    3. Background openFDA drug label record for Multaq (dronedarone tablets), Sanofi-Aventis U.S. LLC label: indications, mechanism, class, boxed warning

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 7fa41601-7fb5-4155-8e50-2ae903f0d2d6 (manufacturer Sanofi-Aventis U.S. LLC, application NDA022425), returned on 2026-11-18. The label text is dated 2025-05-29 (effective_time). A second openFDA Multaq record (Cardinal Health 107, LLC, a repackager) exists and was not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20250529.
      Retrieved
      Source effective date
      2025-05-29
      Source state
      Current
      Version fingerprint
      54147fc8a2984100b211341d515c2f61f7f9f0d9415ddba75659fe6d841df662
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

Clinical links

Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.

Record details

Record id
cardio:dronedarone
Content hash
cd5dbb65968ef550f8a45a68f369cb85b500d1cc25ad9e00884c1372438c1798